Eli Lilly and Company logo

Eli Lilly and Company (LLY)

Market Open
4 Jun, 13:37
NYSE NYSE
$
1,107. 38
+28.6
+2.6511%
$
1.02T Market Cap
104.2 P/E Ratio
0.05% Div Yield
418,896 Volume
6.64 Eps
$ 1,078.78
Previous Close
Add Transaction
Day Range
1,101.65 1,111.62
Year Range
623.78 1,149.1
Want to track LLY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Eli Lilly (LLY) Laps the Stock Market: Here's Why

Eli Lilly (LLY) Laps the Stock Market: Here's Why

In the closing of the recent trading day, Eli Lilly (LLY) stood at $1, denoting a +1.82% move from the preceding trading day.

Zacks | 2 months ago
Eli Lilly says some Medicare plans may exceed $50 cap for weight-loss drugs

Eli Lilly says some Medicare plans may exceed $50 cap for weight-loss drugs

Eli Lilly said on Monday a small number of basic Medicare drug plans may not follow ​the $50 per month cap on out-of-pocket costs for ‌its weight-loss drugs, under the Medicare agency's weight-loss drug coverage model.

Reuters | 2 months ago
Lilly (LLY) Down 3.7% Since Last Earnings Report: Can It Rebound?

Lilly (LLY) Down 3.7% Since Last Earnings Report: Can It Rebound?

Lilly (LLY) reported earnings 30 days ago. What's next for the stock?

Zacks | 2 months ago
What Are The Biggest Risks To Eli Lilly Stock?

What Are The Biggest Risks To Eli Lilly Stock?

Eli Lilly stock (LLY) is currently trading near $1,000, reflecting a decline of over 11% from its 52-week high as investors recalibrate expectations against emerging headwinds.

Forbes | 3 months ago
Lilly Stock Down 5% in a Month: Should You Buy Now or Steer Clear?

Lilly Stock Down 5% in a Month: Should You Buy Now or Steer Clear?

LLY's shares fall 5% in a month amid pricing fears and obesity-drug rivalry, but booming Mounjaro and Zepbound sales and a deep pipeline keep growth hopes alive.

Zacks | 3 months ago
Eli Lilly launches program to help boost employer coverage of obesity drugs in U.S.

Eli Lilly launches program to help boost employer coverage of obesity drugs in U.S.

Eli Lilly launched a new program designed to help more employers cover obesity drugs in the U.S., targeting a major barrier to access for patients.  The "Employer Connect" platform gives employers more flexibility in how they cover obesity treatments, aiming to broaden employee access to the drugs at low out-of-pocket costs, while also keeping costs within budgets.

Cnbc | 3 months ago
Forget AI. This Biotech Stock's Taking Off Right Now

Forget AI. This Biotech Stock's Taking Off Right Now

The market seems to be falling heavily out of love with the AI stocks, and for good reason: CapEx is rising at a staggering rate, especially among the Mag Seven AI darlings, all while the question marks surrounding ROIs get bigger.

247wallst | 3 months ago
Here's Why Eli Lilly (LLY) is a Strong Momentum Stock

Here's Why Eli Lilly (LLY) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 3 months ago
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks | 3 months ago
Eli Lilly and Company (LLY) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Eli Lilly and Company (LLY) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Eli Lilly and Company (LLY) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Seekingalpha | 3 months ago
LLY Wins CHMP Nod for Olumiant's Expanded Use in Alopecia Areata

LLY Wins CHMP Nod for Olumiant's Expanded Use in Alopecia Areata

Eli Lilly wins CHMP backing to expand Olumiant use in adolescents with severe alopecia areata, with the EU approval decision expected shortly.

Zacks | 3 months ago
What Smart Money Loves About Lilly

What Smart Money Loves About Lilly

Eli Lilly (NYSE: LLY) stock has pulled back 2.9% year-to-date to around $1,044, and institutional investors have been accumulating shares during the pullback, according to recent filings.

247wallst | 3 months ago
Loading...
Load More